SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

Data : 18/10/2019 @ 17:50
Fonte : PR Newswire (US)
Ativo : Achillion Pharmaceuticals Inc (ACHN)
Cotação : 6.19  -0.05 (-0.80%) @ 20:01
Cotação Gráfico
Último Negócio
no After Hours
Último $ 6,19 ◊ 0,00 (0,00%)

SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals (NASDAQ:ACHN)
Gráfico Histórico do Ativo

3 Meses : De Out 2019 até Jan 2020

Click aqui para mais gráficos Achillion Pharmaceuticals.

NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Achillion Pharmaceuticals, Inc. ("ACHN" or the "Company") (NASDAQ: ACHN) in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc. ("ALXN") (NASDAQ: ALXN).  Under the terms of the acquisition agreement, ACHN shareholders will receive $6.30 cash for each ACHN share they own. 

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own ACHN shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/achillion-pharmaceuticals-inc/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com 

WeissLaw is investigating whether ACHN's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, the Company currently has two clinical stage treatments in development, including Danicopan, a lead drug candidate which has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration ("FDA") for treatment of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria, or PNH.  Receiving Breakthrough Therapy designation from the FDA indicates preliminary clinical evidence has demonstrated the drug may provide substantial improvement on at least one clinically significant endpoint compared with currently available therapy.

Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-achillion-pharmaceuticals-inc-300941386.html

SOURCE WeissLaw LLP

Copyright 2019 PR Newswire

Seu Histórico Recente
BOV
VALE5
Vale PNA
BOV
IBOV
iBovespa
BOV
PETR4
Petrobras
BOV
IGBR3
IGB SA
FX
USDBRL
Dólar EUA ..
Ações já vistas aparecerão nesta caixa, facilitando a volta para cotações pesquisadas anteriormente.

Registre-se agora para criar sua própria lista de ações customizada.

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4950 5808.
P: V:br D:20200117 23:49:43